Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA declines to approve pre-filled syringe version of Regeneron’s Eylea

The U.S. FDA declined to approve a pre-filled syringe version of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea.

Read More »

Eylea Shows Promising Data for Diabetic Retinopathy

Regeneron Pharmaceuticals announced positive top-line data from the Phase III PANORAMA study of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.

Read More »

Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema

Genentech announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.

Read More »

Momenta, Mylan plan biosimilar clinical trial

Momenta Pharmaceuticals and Mylan plan to begin a pivotal clinical study of a biosimilar to Regeneron’s blockbuster eye drug Eylea in first-half 2018.

Read More »

KalVista Reaches $760 Million Deal With Merck

KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.

Read More »

Roche, Eleven Bio Ink $300 Million Deal

Roche was granted an exclusive, worldwide license to develop and commercialize all IL-6 antagonist antibody technology owned by Eleven Biotherapeutics.

Read More »

Eleven Bio Forges Deal with Roche

Eleven Biotherapeutics struck a $270 million deal with Roche to develop Eleven’s experimental EBI-031 treatment for eye-related diseases.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom